Clinical Trial Update: ARAMIS: Actions of tesaglitazaR on fAt Metabolism and Insulin Sensitivity [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating tesaglitazar's effects on fat metabolism and insulin sensitivity in Type 2 diabetes was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Tesaglitazar (tesaglitazar)

Snippet

Sponsor: AstraZeneca | Conditions: Type 2 Diabetes | Phase 2 | Status: TERMINATED